Cargando…

721. In Vitro Activity of Cefiderocol Against Gram-Negative Clinical Isolates From New York City

BACKGROUND: Multidrug-resistant Gram-negative bacteria have become a serious problem in hospitals worldwide. Cefiderocol (CFDC) is a novel siderophore cephalosporin with activity against a wide range of carbapenemase- and ESBL-producing bacteria. We tested the activity of CFDC against (1) a recent c...

Descripción completa

Detalles Bibliográficos
Autores principales: Iregui, Alejandro, Khan, Zeb, Landman, David, Quale, John M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6811323/
http://dx.doi.org/10.1093/ofid/ofz360.789
_version_ 1783462456716165120
author Iregui, Alejandro
Khan, Zeb
Landman, David
Quale, John M
author_facet Iregui, Alejandro
Khan, Zeb
Landman, David
Quale, John M
author_sort Iregui, Alejandro
collection PubMed
description BACKGROUND: Multidrug-resistant Gram-negative bacteria have become a serious problem in hospitals worldwide. Cefiderocol (CFDC) is a novel siderophore cephalosporin with activity against a wide range of carbapenemase- and ESBL-producing bacteria. We tested the activity of CFDC against (1) a recent collection of clinical isolates and (2) a separate collection of carbapenem-resistant isolates gathered from NYC hospitals. METHODS: Susceptibility testing was performed on isolates of E. coli, K. pneumoniae, Enterobacter spp., P. aeruginosa, and A. baumannii gathered in 2017 from 7 hospitals in Brooklyn, NY. Consecutive unique patient clinical isolates from all sources were collected for a three month period. Testing was also done on a collection of carbapenem-resistant isolates from a similar surveillance study conducted in 2013–2014. MICs were performed with iron-depleted cation-adjusted Mueller–Hinton broth for CFDC and agar dilution for other antibiotics according to CLSI methodology. The provisional CLSI breakpoint (≤4 μg/mL susceptible) was used for CFDC. Cephalosporin-resistant isolates were tested for common carbapenemases by PCR. RESULTS: The susceptibility results for CFDC and meropenem for the isolates gathered in 2017 are listed in the Table. All of the Enterobacteriacae were susceptible to CFDC including KPC-possessing E. coli (n = 4), K. pneumoniae (n = 20), and Enterobacter spp (n = 3). 99.6% of P. aeruginosa and 100% of A. baumannii (including 8 with bla(OXA-23), 2 with bla(OXA-24), and 1 with bla(KPC)) were susceptible to CFDC. For the collection of carbapenem-resistant isolates gathered in 2013–14, 100% of K. pneumoniae (n = 111), 100% of P. aeruginosa (n = 130), and 90% of A. baumannii (n = 78) were susceptible to CFDC. CONCLUSION: CFDC has excellent in vitro activity against Gram-negative clinical isolates from NYC, including a large collection of carbapenem-resistant Enterobacteriaceae, P. aeruginosa, and A. baumannii. [Image: see text] DISCLOSURES: All authors: No reported disclosures.
format Online
Article
Text
id pubmed-6811323
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-68113232019-10-29 721. In Vitro Activity of Cefiderocol Against Gram-Negative Clinical Isolates From New York City Iregui, Alejandro Khan, Zeb Landman, David Quale, John M Open Forum Infect Dis Abstracts BACKGROUND: Multidrug-resistant Gram-negative bacteria have become a serious problem in hospitals worldwide. Cefiderocol (CFDC) is a novel siderophore cephalosporin with activity against a wide range of carbapenemase- and ESBL-producing bacteria. We tested the activity of CFDC against (1) a recent collection of clinical isolates and (2) a separate collection of carbapenem-resistant isolates gathered from NYC hospitals. METHODS: Susceptibility testing was performed on isolates of E. coli, K. pneumoniae, Enterobacter spp., P. aeruginosa, and A. baumannii gathered in 2017 from 7 hospitals in Brooklyn, NY. Consecutive unique patient clinical isolates from all sources were collected for a three month period. Testing was also done on a collection of carbapenem-resistant isolates from a similar surveillance study conducted in 2013–2014. MICs were performed with iron-depleted cation-adjusted Mueller–Hinton broth for CFDC and agar dilution for other antibiotics according to CLSI methodology. The provisional CLSI breakpoint (≤4 μg/mL susceptible) was used for CFDC. Cephalosporin-resistant isolates were tested for common carbapenemases by PCR. RESULTS: The susceptibility results for CFDC and meropenem for the isolates gathered in 2017 are listed in the Table. All of the Enterobacteriacae were susceptible to CFDC including KPC-possessing E. coli (n = 4), K. pneumoniae (n = 20), and Enterobacter spp (n = 3). 99.6% of P. aeruginosa and 100% of A. baumannii (including 8 with bla(OXA-23), 2 with bla(OXA-24), and 1 with bla(KPC)) were susceptible to CFDC. For the collection of carbapenem-resistant isolates gathered in 2013–14, 100% of K. pneumoniae (n = 111), 100% of P. aeruginosa (n = 130), and 90% of A. baumannii (n = 78) were susceptible to CFDC. CONCLUSION: CFDC has excellent in vitro activity against Gram-negative clinical isolates from NYC, including a large collection of carbapenem-resistant Enterobacteriaceae, P. aeruginosa, and A. baumannii. [Image: see text] DISCLOSURES: All authors: No reported disclosures. Oxford University Press 2019-10-23 /pmc/articles/PMC6811323/ http://dx.doi.org/10.1093/ofid/ofz360.789 Text en © The Author(s) 2019. Published by Oxford University Press on behalf of Infectious Diseases Society of America. http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Abstracts
Iregui, Alejandro
Khan, Zeb
Landman, David
Quale, John M
721. In Vitro Activity of Cefiderocol Against Gram-Negative Clinical Isolates From New York City
title 721. In Vitro Activity of Cefiderocol Against Gram-Negative Clinical Isolates From New York City
title_full 721. In Vitro Activity of Cefiderocol Against Gram-Negative Clinical Isolates From New York City
title_fullStr 721. In Vitro Activity of Cefiderocol Against Gram-Negative Clinical Isolates From New York City
title_full_unstemmed 721. In Vitro Activity of Cefiderocol Against Gram-Negative Clinical Isolates From New York City
title_short 721. In Vitro Activity of Cefiderocol Against Gram-Negative Clinical Isolates From New York City
title_sort 721. in vitro activity of cefiderocol against gram-negative clinical isolates from new york city
topic Abstracts
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6811323/
http://dx.doi.org/10.1093/ofid/ofz360.789
work_keys_str_mv AT ireguialejandro 721invitroactivityofcefiderocolagainstgramnegativeclinicalisolatesfromnewyorkcity
AT khanzeb 721invitroactivityofcefiderocolagainstgramnegativeclinicalisolatesfromnewyorkcity
AT landmandavid 721invitroactivityofcefiderocolagainstgramnegativeclinicalisolatesfromnewyorkcity
AT qualejohnm 721invitroactivityofcefiderocolagainstgramnegativeclinicalisolatesfromnewyorkcity